Gid Group S Svf 2 Device And Therapypending Fda Approvalgives Providers And Patients A Major Development In Cellular Medicine To Help Treat Osteoarthritis Pain And To Delay Or Provide An Alternative To Total Knee Replacement Surgerygid S Technology Harvestsisolate And Reimplants The Right Type And Combination Of One S Own Healing Cellsour First Fda Approved Pivotal Clinical Studya Closely Watched Rigorous Trialhad No Serious Adverse Events And Showed Significant Improvements In Pain And Functionthe Fda Has Granted Conditional Approval For A Second Final Pivotal Clinical Trialcellular Therapy Addresses An Unmet Need In 14 Million People Living With Osteoarthritis Of The Kneeoffering A Less Time Consumingpainful And Costly Treatment For Everyone That Requires No Joint Surgery And No Drugs For Osteoarthritis Painhelp Relieve The $200 Billion Burden Of Osteoarthritis Management On Our Healthcare Systemheal Intelligently
